Heidelberg Pharma AG (HPHA) - Net Assets
Based on the latest financial reports, Heidelberg Pharma AG (HPHA) has net assets worth €18.52 Million EUR (≈ $21.65 Million USD) as of May 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€62.45 Million ≈ $73.02 Million USD) and total liabilities (€43.94 Million ≈ $51.37 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Read HPHA current and long-term liabilities for a breakdown of total debt and financial obligations.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €18.52 Million |
| % of Total Assets | 29.65% |
| Annual Growth Rate | 15.48% |
| 5-Year Change | 139.66% |
| 10-Year Change | N/A |
| Growth Volatility | 309.68 |
Heidelberg Pharma AG - Net Assets Trend (2016–2024)
This chart illustrates how Heidelberg Pharma AG's net assets have evolved over time, based on quarterly financial data. Also explore Heidelberg Pharma AG total assets for the complete picture of this company's asset base.
Annual Net Assets for Heidelberg Pharma AG (2016–2024)
The table below shows the annual net assets of Heidelberg Pharma AG from 2016 to 2024. For live valuation and market cap data, see Heidelberg Pharma AG market cap and net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2024-11-30 | €30.87 Million ≈ $36.09 Million |
-37.44% |
| 2023-11-30 | €49.34 Million ≈ $57.68 Million |
-25.97% |
| 2022-11-30 | €66.64 Million ≈ $77.91 Million |
+894.88% |
| 2021-11-30 | €6.70 Million ≈ $7.83 Million |
-47.99% |
| 2020-11-30 | €12.88 Million ≈ $15.06 Million |
-20.96% |
| 2019-11-30 | €16.29 Million ≈ $19.05 Million |
-37.06% |
| 2018-11-30 | €25.89 Million ≈ $30.26 Million |
-30.08% |
| 2017-11-30 | €37.02 Million ≈ $43.28 Million |
+279.49% |
| 2016-11-30 | €9.76 Million ≈ $11.41 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Heidelberg Pharma AG's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 13687463100.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (November 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €361.99 Million | 1172.78% |
| Total Equity | €30.87 Million | 100.00% |
Heidelberg Pharma AG Competitors by Market Cap
The table below lists competitors of Heidelberg Pharma AG ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Multitude SE
LSE:0R4W
|
$139.98 Million |
|
CSC Steel Holdings Bhd
KLSE:5094
|
$140.01 Million |
|
D-Box Technologies Inc.
TO:DBO
|
$140.06 Million |
|
Betr Entertainment Ltd
AU:BBT
|
$140.08 Million |
|
BANK OF JIUJIANG H YC1
F:BJ8
|
$139.86 Million |
|
YFC-BonEagle Electric Co Ltd
TWO:6220
|
$139.82 Million |
|
Abonmax Co Ltd
TW:2429
|
$139.80 Million |
|
TH Plantations Bhd
KLSE:5112
|
$139.80 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Heidelberg Pharma AG's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 49,339,796 to 30,865,735, a change of -18,474,061 (-37.4%).
- Net loss of 19,381,995 reduced equity.
- New share issuances of 22,760,781 increased equity.
- Other factors decreased equity by 21,852,847.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-19.38 Million | -62.79% |
| Share Issuances | €22.76 Million | +73.74% |
| Other Changes | €-21.85 Million | -70.8% |
| Total Change | €- | -37.44% |
Book Value vs Market Value Analysis
This analysis compares Heidelberg Pharma AG's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.05x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 1.63x to 4.05x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-11-30 | €1.65 | €2.68 | x |
| 2018-11-30 | €0.92 | €2.68 | x |
| 2019-11-30 | €0.58 | €2.68 | x |
| 2020-11-30 | €0.41 | €2.68 | x |
| 2021-11-30 | €0.20 | €2.68 | x |
| 2022-11-30 | €1.43 | €2.68 | x |
| 2023-11-30 | €1.06 | €2.68 | x |
| 2024-11-30 | €0.66 | €2.68 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Heidelberg Pharma AG utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -62.79%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -282.98%
- • Asset Turnover: 0.11x
- • Equity Multiplier: 1.97x
- Recent ROE (-62.79%) is above the historical average (-96.55%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | -65.49% | -469.09% | 0.09x | 1.56x | €-7.36 Million |
| 2017 | -29.63% | -577.38% | 0.05x | 1.12x | €-14.67 Million |
| 2018 | -45.09% | -318.21% | 0.12x | 1.20x | €-14.26 Million |
| 2019 | -62.28% | -138.84% | 0.32x | 1.41x | €-11.78 Million |
| 2020 | -142.63% | -216.41% | 0.43x | 1.52x | €-19.66 Million |
| 2021 | -390.20% | -1493.79% | 0.08x | 3.24x | €-26.81 Million |
| 2022 | -29.56% | -106.42% | 0.18x | 1.51x | €-26.37 Million |
| 2023 | -41.24% | -206.38% | 0.14x | 1.43x | €-25.28 Million |
| 2024 | -62.79% | -282.98% | 0.11x | 1.97x | €-22.47 Million |
Industry Comparison
This section compares Heidelberg Pharma AG's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $979,793,893
- Average return on equity (ROE) among peers: -18.73%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Heidelberg Pharma AG (HPHA) | €18.52 Million | -65.49% | 2.37x | $139.89 Million |
| TIZIANA LIFE SCIENCES LTD (0RP) | $5.54 Million | -319.56% | 1.20x | $157.03 Million |
| Theravance Biopharma Inc (0TB) | $441.80 Million | 197.40% | 0.37x | $828.57 Million |
| PreveCeutical Medical Inc (18H) | $-3.60 Million | 0.00% | 0.00x | $3.34 Million |
| Argen-X (1AE) | $2.53 Billion | -16.11% | 0.12x | $44.01 Billion |
| WAVE LIFE SCIENCES LTD. (1U5) | $-45.09 Million | 0.00% | 0.00x | $1.12 Billion |
| ZAI LAB LTD0000006 (1ZLB) | $840.90 Million | -30.57% | 0.41x | $2.05 Billion |
| BioNTech SE (22UA) | $1.37 Billion | 1.11% | 0.69x | $23.24 Billion |
| Ascletis Pharma Inc (2VJ) | $2.98 Billion | -7.02% | 0.03x | $2.05 Billion |
| ALPHAMAB ONCOLO.DL-000002 (3NK) | $1.67 Billion | -12.59% | 0.28x | $978.26 Million |
| BIOMIND LABS INC. (3XI) | $-1.43 Million | 0.00% | 0.00x | $3.31 Million |
About Heidelberg Pharma AG
Heidelberg Pharma AG, a biopharmaceutical company, focuses on oncology and antibody targeted amanitin conjugates (ATAC) in Germany, the United States, and internationally. Its lead product candidates include HDP-101, an anti-BCMA antibody, which in the Phase I/IIa study for the treatment of relapsed or refractory multiple myeloma. The company develops HDP-102, an antibody and the compound Amaniti… Read more